. non-pharmaceutical ongoing r&d expenses , after adjusting for the following items , were up approximately 11% ( 11 % ) in dollars , as the company continued to aggressively invest in future technologies and growth opportunities . 2006 spending included a $ 95 million in-process research and development charge ( discussed in note 2 ) and $ 75 million in restructuring actions ( note 4 ) , which increased 2006 r&d as a percent of sales by 0.7 percentage points